-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Drug Discovery Programme
Second Global Dementia Legacy Event: Ottawa, September 11th/12th 2014 (Department of Health / Dementia Challenge / World Dementia Council / CIHR / AVIESAN)
Summary Canada and France are co-hosting the second Global Action Against Dementia Legacy Event in Ottawa (Canada) on September 11th – 12th 2014. This event will explore how to take advantage of partnership working and collaboration between industry and academia, … Continue reading →
Posted in Acute Hospitals, Community Care, Department of Health, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Patient Care Pathway, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, Universal Interest
|
Tagged Academia-Industry Partnerships, Academia-Industry Synergies, Academic-Industry Collaborations, Alain Beaudet: President of Canadian Institutes of Health Research (CIHR), Alice Wong: Minister of State (Seniors) in Canada, Alzheimer Society of Canada, AVIESAN: French National Alliance for Life Sciences and Health, •Alzheimer Society of Canada, Big Data, Biotechnology, Canada, Canada's Research Strategy for Alzheimer's Disease, Canada-France Legacy Event, Canadian Institutes of Health Research (CIHR), Challenge on Dementia, Challenge on Dementia (David Cameron), Collaboration, Collaborative Projects, Cross-Sector Partnerships, Dementia Challenge, Dementia in Canada, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Dennis Gillings: Former World Dementia Envoy, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug-Development Pipeline, Faye Forbes (Living With Dementia), France, Free Open Access Journals, G7 Global Dementia Summit, G8 Dementia Summit, G8 Dementia Summit Agreements, G8 Summit on Dementia Communique, G8 Summit on Dementia Declaration, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Global Dementia Legacy Event on Academia-Industry Synergies, Global Leadership, Global Outlook, Incentives and Investment, Incentives for Drug Development, Innovation, Innovative Medicines Initiative, Institute of Health and Medical Research (Inserm), International Collaborations, International Programmes, Japan Legacy Event, Knowledge Networks, Knowledge Translation, Massachusetts Biotech Cluster: CONNECT, Matthew Dineen (Carer), Medical Devices, Networks, Networks and Alliances, Neurological Research, OECD Big Data and Sustainability Initiative for Large-Scale Research on Dementia, Open Access, Open Access Databases, Open Access Journals, Open Access Knowledge Resources, Open Access Research, Partnership, Partnership and Collaboration, Partnership Working, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, Philippe Zeller: Ambassador of France to Canada, Prime Minister's Challenge on Dementia, Prime Minister’s Dementia Challenge, Regulatory Barriers: Regulatory Environment, Removing Regulatory Barriers, Research and Innovation, Research Networks, Resource and Incentives, Second Global Dementia Legacy Event, Second Global Dementia Legacy Event (Ottawa: September 2014), The Honourable Rona Ambrose: Minister of Health (Canada), UK Legacy Event, USA Legacy Event, Venture Capital (Approach to Research), World Dementia Council, Yves Lévy: French National Institute of Health and Medical Research (Inserm) and Chairman of Aviesan (French National Alliance for Life Sciences and Health Care)
|
Leave a comment
Blood Test Potentially Able to Predict Alzheimer’s Disease Onset (BBC News / Alzheimer’s & Dementia)
Summary Research published in the Alzheimer’s & Dementia: the Journal of the Alzheimer’s Association may indicate a significant step forwards in developing a blood test which could be able to predict the risk of Alzheimer’s Disease onset with 87% accuracy. Research … Continue reading →
Posted in BBC News, Charitable Bodies, For Doctors (mostly), For Researchers (mostly), In the News, International, Quick Insights, UK, Universal Interest
|
Tagged A2M (Protein), A2M: Alpha-2-Macroglobulin, Ab40 (Protein), AddNeuroMed Consortium, Alzheimer's Association, Alzheimer's Disease: Diagnosis, Alzheimer’s & Dementia: the Journal of the Alzheimer's Association, Alzheimer’s Early Screening, Amyloid-β (Aβ), ApoA1 (Protein), ApoE (Protein), Aristotle University, B2M (Protein), BBC Health News, BDNF (Protein), Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Tests, Blood-Based Biomarkers, Brain Imaging, Brain Research, Case Finding, CathepsinD (Protein), Ceruloplasmin (Protein), CFH (Protein), CFH: Complement Factor H, Clinical Dementia Rating Scale, Clinical Trials and Treatment Assessments, Clusterin, Cognitive Impairment, Conversion to Dementia From Prodromal Disease, CRP: C-Reactive Protein, Dementia Case Finding, Dementia Consortium, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurobiology Care Sciences and Society: Karolinska Institutet, Department of Neuroimaging Genetics: QIMR Berghofer Medical Research Institute, Department of Old Age Psychiatry: King's College London, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Diagnostics, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug Trials Failure Rate, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Differential Diagnosis, Early Screening, EMD Millipore Corporation, Exeter University, George Washington University School of Medicine and Health Sciences, GlaxoSmithKline Medicines Research Centre, Global Clinical Development Fund, INSERM: University of Toulouse, Kings College London, Kuopio University Hospital, Lund University, Lund University (Sweden), Magnetic Resonance Imaging (MRI), McGill Centre for Studies in Aging, MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), MMSE: Mini-Mental State Examination, MRI Scans, NCAM (Protein), Non-Invasive Biomarkers, NSE (Protein), NSE: Neuron-Specific Enolase, p-tau217, Pharmaceutical Industry, Plasma Aβ Peptides, Plasma Proteins, Prealbumin (Protein), Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Proteome Sciences plc, QIMR Berghofer Medical Research Institute, RANTES (Protein), RANTES: Regulated on Activation Normal T Cell Expressed and Secreted, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Structural MRI, Translational Research, TTR: Transthyretin, University of Eastern Finland, University of Exeter Medical School: Exeter University, University of Oxford, University of Perugia, University of Toulouse, VCAM1 (Protein), Washington University School of Medicine
|
Leave a comment
Decline in Number of Clinical Trials for Alzheimer’s Disease (BBC News / Alzheimer’s Research & Therapy)
Summary More than 99% of drug trials for Alzheimer’s Disease during the past decade have failed. An article in the Alzheimer’s Research & Therapy journal discusses an issue which was perhaps the key focus of the Global Dementia Legacy Event. … Continue reading →
Posted in Alzheimer’s Disease International (ADI), Alzheimer’s Research UK, BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Standards, Universal Interest
|
Tagged Alzheimer’s Disease Clinical Trials, Amyloid Cascade Hypothesis, Anti-Amyloid Combination Therapy, Antidementia Drugs, Aston University, BBC Health News, Big Pharma, Brain Research, Cleveland Clinic Lou Ruvo Center for Brain Health: Las Vegas, Clinical Trials and Treatment Assessments, Dementia Innovation, Dementia Research, Dementia Time-Bomb, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programme, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Action Against Dementia, Global Context, Global Dementia Legacy Event, Incentives for Drug Development, Neurological Research, Payment Systems and Incentives, Pharmaceutical Industry, Pharmacological Research, R&D Productivity, Touro University Nevada College of Osteopathic Medicine, Translational Research
|
Leave a comment
Annual Progress Report(s) on Prime Minister’s Dementia Challenge (Department of Health / Dementia Challenge)
Summary The three Dementia Challenge Champion Groups have written brief reports detailing their progress during the past year. These reports feature in a letter to the Prime Minister (see below), which also reiterates achievements since the Prime Minister’s Dementia Challenge … Continue reading →
Posted in Acute Hospitals, Commissioning, Community Care, Department of Health, Diagnosis, End of Life Care, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Health Education England (HEE), In the News, Integrated Care, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, Patient Care Pathway, Person-Centred Care, Personalisation, Quick Insights, Standards, UK, Universal Interest
|
Tagged 6Cs Live!, 6Cs Live! Communications Hub, 6Cs Live! Website, Accuracy of Dementia Prevalence Data, Alborada Trust, Alzheimer's Research UK, Alzheimer’s Research UK Drug Discovery Institute, Alzheimer’s Society’s Drug Discovery Programme, Awareness Raising, Best Practice for Dementia Care, Better Care Fund and Integration Pioneers, Black and Minority Ethnic (BME), Black and Minority Ethnic Older People, BME Communities, BME: Black and Minority Ethnic, Breakthrough Challenge for Dementia, British Standards Institution (BSI), British Standards Institution (BSI): Code of Practice for Dementia Friendly Communities, Building Dementia Friendly Communities, Care England, Caregiver Support, Carer Support, Carers Call to Action, Carers Included: A Guide to Best Practice in Acute Mental Health Care, Centres of Excellence in Neurodegeneration Initiative (CoEN), Centres of Excellence in Neurodegenerative disease (CoEN) Pathfinder Grants, Challenge on Dementia (David Cameron), Clinical Research Networks, Code of Practice for Dementia Friendly Communities, Curriculum for Dementia Education (CfDE), Data Sharing, Dementia and Homecare, Dementia Assessment and Referral Data, Dementia Awareness, Dementia Care and Support Compact, Dementia Case Records Interactive Search System, Dementia Challenge, Dementia Challenge Champion Groups, Dementia Choices (NHS Choices), Dementia Commissioning for Quality and Innovation (CQUIN), Dementia Commissioning for Quality and Innovation (CQUIN) Reward, Dementia Diagnosis, Dementia Directed Enhanced Service (DES), Dementia Friendly Awards, Dementia Friendly Churches Sermon Pack, Dementia Friendly Communities Champion Group, Dementia Friendly Communities Programme, Dementia Friendly Communities Recognition Process, Dementia Friendly Communities Recognition Process: Barnsley, Dementia Friendly Communities Recognition Process: Bexhill, Dementia Friendly Communities Recognition Process: Bourne, Dementia Friendly Communities Recognition Process: Bracknell Forest, Dementia Friendly Communities Recognition Process: Bradford, Dementia Friendly Communities Recognition Process: Bury, Dementia Friendly Communities Recognition Process: Camelford, Dementia Friendly Communities Recognition Process: Corbridge, Dementia Friendly Communities Recognition Process: Coventry, Dementia Friendly Communities Recognition Process: Crawley, Dementia Friendly Communities Recognition Process: Deal, Dementia Friendly Communities Recognition Process: Debenham, Dementia Friendly Communities Recognition Process: Doncaster, Dementia Friendly Communities Recognition Process: Falmouth, Dementia Friendly Communities Recognition Process: Gedling, Dementia Friendly Communities Recognition Process: Hampshire, Dementia Friendly Communities Recognition Process: Kent, Dementia Friendly Communities Recognition Process: Lancaster Morecambe and District, Dementia Friendly Communities Recognition Process: Leeds, Dementia Friendly Communities Recognition Process: Liverpool, Dementia Friendly Communities Recognition Process: London Borough of Richmond, Dementia Friendly Communities Recognition Process: Luton, Dementia Friendly Communities Recognition Process: Malpas, Dementia Friendly Communities Recognition Process: Manchester, Dementia Friendly Communities Recognition Process: Marple (Stockport), Dementia Friendly Communities Recognition Process: Newbury, Dementia Friendly Communities Recognition Process: North and Northeast Lincolnshire, Dementia Friendly Communities Recognition Process: Peterborough, Dementia Friendly Communities Recognition Process: Plymouth, Dementia Friendly Communities Recognition Process: Poole, Dementia Friendly Communities Recognition Process: Portsmouth, Dementia Friendly Communities Recognition Process: Salford, Dementia Friendly Communities Recognition Process: Sandwell, Dementia Friendly Communities Recognition Process: Sheffield, Dementia Friendly Communities Recognition Process: Stockon, Dementia Friendly Communities Recognition Process: Surrey, Dementia Friendly Communities Recognition Process: Tavistock, Dementia Friendly Communities Recognition Process: The Parishes of Wembury Brixton Yealmpton Newton and Noss and Holbeton, Dementia Friendly Communities Recognition Process: Thurrock, Dementia Friendly Communities Recognition Process: Tring, Dementia Friendly Communities Recognition Process: Wakefield, Dementia Friendly Communities Recognition Process: Warwickshire, Dementia Friendly Communities Recognition Process: Wimborne, Dementia Friendly Communities Recognition Process: Windsor and Maidenhead, Dementia Friendly Communities Recognition Process: Wokingham, Dementia Friendly Communities Recognition Process: Wolverhampton, Dementia Friendly Communities Recognition Process: Worthing, Dementia Friendly Communities Recognition Process: York, Dementia Friendly Communities Recognition Process: Yorkshire, Dementia Friendly Financial Services Charter, Dementia Friendly Technologies, Dementia Friends, Dementia Friends Campaign, Dementia Health and Care Champion Group, Dementia Resource Suite for Schools, Dementia Roadmap Web-Based Tool, Dementia Technology Charter, Dementia-Friendly Businesses, Dementia-Friendly Cities, Dementia-Friendly Communities, Dementia-Friendly Environments, Dementia-Friendly Hospitals, Dementia-Friendly Industries, Dementia-Friendly Neighbourhoods, Dementia-Friendly Organisations, Dementia-Friendly Sectors, Dementia-Friendly Shops, Dementia-Friendly Towns, Dementia-Friendly Yorkshire, DementiaChoices Website, Dementias and Neurodegenerative Diseases Research Network (DeNDRoN), DeNDRoN: Dementias and Neurodegenerative Diseases Research Network, Dennis Gillings: Former World Dementia Envoy, Department of Health’s Post Diagnosis Working Group, Diagnosis Rates, Diagnosis Rates Ambition (UK), Directed Enhanced Service (DES), Doctoral Training Centres, Drug Discovery Institute, Drug Discovery Programme, Drug Discovery Programme (Alzheimer's Society), Early Intervention Dementia Service, Early Intervention Dementia Service in Worcestershire, Economic and Social Research Council (ESRC), Enabling Research in Care Homes (ENRICH), Engaging Businesses in Dementia Friends, ENRICH: Enabling Research in Care Homes, ENRICH: Toolkit for Care Home Research, ESRC: Economic and Social Research Council, EU Joint Programme in Neurodegenerative Disease (JPND), EU Joint Programme: Neurodegenerative Disease Research (JPND), Faith Groups, Financial Services Dementia Charter, G8 Dementia Summit, G8 Dementia Summit: Global Action Against Dementia, Global Action Against Dementia, Greenwich Advanced Dementia Service (GADS), Health and Care Champion Group, HEE: Health Education England, HEE’s Investment in Dementia Education and Training, Higher Education for Dementia Network (HEDN), IAPT: Improving Access to Psychological Therapies, Identification and Validation of Therapeutic Targets, Improving Access to Psychological Therapies (IAPT) Programme, Innovation Challenge Prize for Dementia, International Programmes, International Research, Janssen Healthcare Innovation, Join Dementia Research National Service, Join Dementia Research: Recruitment Onto Dementia Studies, JPND Research Projects, JPND: Joint Programme on Neurodegenerative Disease Research, Knowledge Translation, Laboratory of Molecular Biology (LMB) Neuroscience Division, Lifestyle Factors, Lifestyle Risk Factors, Liviability, Liviability: Dementia Friendly Churches Sermon Pack, Living Well After Diagnosis, Local Dementia Action Alliances, Local Dementia Action Alliances in England, London School of Economics, MAGDR: Ministerial Advisory Group on Dementia Research, Medical Research Council (MRC), Memory First, Memory First (Staffordshire), Memory Services National Accreditation Programme, Memory Services National Accreditation Programme (MSNAP), Ministerial Advisory Group on Dementia Research (MAGDR), MRC UK Dementias Research Platform (UKDP), MSNAP: Memory Services National Accreditation Programme, National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs), National Council for Palliative Care, National Institute for Health Research (NIHR), National Minimum Data Set for Social Care, National Minimum Data Set for Social Care: Skills for Care, National Strategic Clinical Network (SCN) for Mental Health, NHS Innovation Challenge Prize for Dementia, NIHR Biomedical Research Centres, NIHR Biomedical Research Units, NIHR Dementia Translational Research Centre, Nursing and Care Quality Forum, Participation in Research, Patient Involvement in Research, Personal Social Services Survey of Adult Carers in England, Personalised Care Planning, Personalised Care Plans, Post-Diagnosis Support, Post-Diagnostic Dementia Support, Post-Diagnostic Support, Power of Attorney, Prevention of Dementia, Prime Minister's Challenge on Dementia, Prime Minister’s Challenge on Dementia: Annual Reports (2014), Prime Minister’s Challenge on Dementia: Progress in Year Two, Prime Minister’s Dementia Challenge, Professor Martin Rossor: NIHR National Director for Dementia Research, Professor Patrick Maxwell, Public Awareness, Public Health England, Public Involvement in Research, Qualification and Credit Framework, Reducing Delays in Dementia Diagnosis, Referral and Assessment, Research Spending on Dementia, Responding to Dementia: Inclusion for All, Skills for Care, Stem Cell Research Centre, Strategic Clinical Network: Mental Health; Dementia and Neurological Conditions, Strategic Clinical Networks, Strategic Clinical Networks (SCNs), Support for Carers, Support for Carers of People with Dementia, Task and Finish Groups, Translational Research, UK Dementias Research Platform, UK Home Care Association, Voluntary Sector
|
Leave a comment
Diabetes Drug Evaluation for Slowing Progression of Alzheimer’s Disease (BBC News)
Summary A trial is underway at Imperial College London, King’s College and sites in Oxford, Southampton and Swindon, to determine whether the drug Liraglutide used to treat diabetes might slow the progression of Alzheimer’s Disease. The study will involve 200 patients with … Continue reading →
Posted in Alzheimer's Society, BBC News, Charitable Bodies, For Researchers (mostly), In the News, Management of Condition, National, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged BBC Health News, Diabetes, Diabetes Prevention, Drug Discovery Programme, GLP-1 Analogue, Imperial College, Inflammation, Liraglutide, Memory Loss, Off-Label Drug Repurposing Trials, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Repurposing of Drugs
|
Leave a comment
